We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hormone Levels Linked to Metabolic Disease

By LabMedica International staff writers
Posted on 04 Sep 2012
An association has been found between low levels of a specific hormone and increased risk of metabolic disease in humans.

The peptide hormone adropin is required for metabolic homeostasis and prevention of obesity-associated insulin resistance and is thought to play a vital role in controlling sugar levels and fatty acid metabolism. More...


A multicenter study led by scientists at The Scripps Research Institute (Jupiter, FL, USA), which included 85 women and 45 men, was carried out to measure adropin levels in serum or plasma in duplicate using a commercially available enzyme-linked immunosorbent assay (ELISA). The lowest detection limit was 0.2 ng/mL and the intraassay coefficient of variation (CV) determined using quality-control human plasma samples with adropin values ranging from 1.1–2.4 ng/mL, was 8.6%.

Lower adropin levels were seen in people with a higher metabolic syndrome risk factor score. This score is based on measuring triglycerides, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL), glucose, blood pressure, and waist circumference. The data suggest that levels of adropin in plasma are stable over time and do not exhibit marked diurnal or meal-related variations. Adropin concentrations increased after Roux-en-Y gastric bypass, peaking three months after surgery. In all subjects, lower age-adjusted adropin levels of 3.3 ng/mL were observed in overweight and 2.7 ng/mL in obese patients compared with 4.1 ng/mL for healthy-weight subjects.

In patients of normal weight, women had lower plasma adropin levels than men, while obesity had a greater adverse effect on adropin levels in men. Obesity in woman was also not connected with lower plasma adropin levels. The team also discovered that adropin levels generally decline with age and was greatest in people over 30 years of age and this was more evident in the male patients. The adropin ELISA used in the study is a product of Peninsula Laboratories, (Bachem; San Carlos, CA, USA).

Andrew A. Butler, Ph., the senior author of the study, said, "The data from these studies provide strong evidence suggesting that low levels of adropin may be an indicator of risk for insulin resistance in obesity and, consequently, an increased risk for metabolic diseases, including type 2 diabetes. We see a lot of similarity between animal model data and the new human data-low adropin levels in humans are associated with a host of metabolic syndrome risk factors normally associated with obesity and insulin resistance." The study was published on August 7, 2012, in the Journal of Clinical Endocrinology and Metabolism.

Related Links:

The Scripps Research Institute
Peninsula Laboratories



Gold Member
Hematology Analyzer
Medonic M32B
Portable Electronic Pipette
Mini 96
Human Estradiol Assay
Human Estradiol CLIA Kit
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.